Clinical trial shows by 2030 that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms
Health & MedicineOne-OffManifold MarketsClosedNo KYCVerified resolution dataFairly calibratedThis market resolved: Yes (77.7%)
Resolved: Oct 3, 2026, 1:08 AM
Provider-verified resolution
CoinRithm has provider-backed winner and settlement-time evidence for this market.
Data quality warningStale data
Data as of Oct 3, 2026, 7:01 AM UTC · policy pm-quality-4
Probability Timeline
Yes77.7%
No22.299999999999997%
Won
Lost
Related Markets
Related questions for context, not a comparison of equivalent contracts.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWill Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
Manifold MarketsWill human tooth regrowth clinical trials succeed?
Manifold MarketsTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurHow many clinical trials will have started in Prospera by Dec 31, 2026?
FutuurRules
Resolution criteria
- This market will resolve to "Yes" if, by December 31, 2030, a peer-reviewed clinical trial demonstrates that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms in humans.
- The trial must be published in a reputable medical journal and show statistically significant improvements in osteoarthritis symptoms compared to a control group.
- The primary outcome measures should include validated assessments of pain, physical function, and/or structural changes in the affected joints.
- If no such study is published by the specified date, the market will resolve to "No".
- If such a study sets out to investigate this and finds no significant reduction of such symptoms before market end date the market also resolves "No".
